Willging S, Keller F, Steinbach G
Abteilung Innere Medizin II, Universitätsklinikum Ulm, Germany.
Clin Chem Lab Med. 1998 Feb;36(2):87-92. doi: 10.1515/CCLM.1998.016.
We investigated and compared serum levels of cardiac troponins I(cTnl) and cardiac troponin T (cTnT) in 85 renal patients (chronic renal impairment n = 23, continuous ambulatory peritoneal dialysis n = 20, hemodialysis n = 42). Patients with the following conditions were excluded: myocardial infarction, angina pectoris, liver disease, malignant neoplasms, enforced physical activity, skeletal muscle trauma, myositis, rhabdomyolysis and seizures. Troponin T was measured by the second generation cTnT-ELISA with a cut-off value = 0.1 microgram/l. Troponin I was measured by a cTnI immunoassay analyser with a cut-off value = 2.0 micrograms/l. Additionally, creatine kinase (CK), CK-MB activity, CK-MB mass concentration and myoglobin levels were measured. Specificity was determined as the fraction of true-negative cases compared to the total number of false-positive and true-negative cases. Specificity for cTnT was 96% [78-100] in patients with renal impairment (creatinine > 150 mumol/l), 95% [75-100] in continuous ambulatory peritoneal dialysis patients, but in hemodialysis patients it was 75% [53-92] for short-term hemodialysis (< 1 year) and 46% [24-68] for long-term hemodialysis (> 1 year). There was a weak correlation between cTnT levels and duration of hemodialysis therapy (r = 0.35, n = 34, p < 0.04). Specificity for cTnI in renal impairment patients was 96% [78-100] and 100% [84-100] in continuous ambulatory peritoneal dialysis and all hemodialysis patients. None of the studied markers showed higher specificity than cTnI. Only myoglobin was less specific than cTnT in hemodialysis patients. Different clearances of the troponins during dialysis (investigated by pre-hemodialysis and post-hemodialysis levels) cannot explain the discordant results of cTnT and cTnI.
Cardiac troponin I exhibits higher specificity than cardiac troponin T in hemodialysis patients. Uremic myopathy could explain falsely elevated troponin T levels in hemodialysis patients.
我们研究并比较了85例肾病患者(慢性肾功能损害23例,持续性非卧床腹膜透析20例,血液透析42例)的血清心肌肌钙蛋白I(cTnI)和心肌肌钙蛋白T(cTnT)水平。排除患有以下疾病的患者:心肌梗死、心绞痛、肝病、恶性肿瘤、强制体力活动、骨骼肌创伤、肌炎、横纹肌溶解症和癫痫发作。采用第二代cTnT-ELISA检测肌钙蛋白T,临界值为0.1微克/升。采用cTnI免疫分析分析仪检测肌钙蛋白I,临界值为2.0微克/升。此外,还检测了肌酸激酶(CK)、CK-MB活性、CK-MB质量浓度和肌红蛋白水平。特异性定义为真阴性病例数占假阳性和真阴性病例总数的比例。肾功能损害患者(肌酐>150微摩尔/升)中cTnT的特异性为96%[78-100],持续性非卧床腹膜透析患者中为95%[75-100],但在血液透析患者中,短期血液透析(<1年)时为75%[53-92],长期血液透析(>1年)时为46%[24-68]。cTnT水平与血液透析治疗时间之间存在弱相关性(r = 0.35,n = 34,p < 0.04)。肾功能损害患者中cTnI的特异性为96%[78-100],持续性非卧床腹膜透析患者和所有血液透析患者中为100%[84-100]。所研究的标志物中没有一个显示出比cTnI更高的特异性。在血液透析患者中,只有肌红蛋白的特异性低于cTnT。透析过程中肌钙蛋白的不同清除率(通过透析前和透析后水平进行研究)无法解释cTnT和cTnI结果的不一致。
在血液透析患者中,心肌肌钙蛋白I的特异性高于心肌肌钙蛋白T。尿毒症性肌病可以解释血液透析患者肌钙蛋白T水平的假性升高。